Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7887-7895

  Nejatollahi, Foroogh ^a,b   Jaberipour, Mansooreh ^c   Asgharpour, Mahdi ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; HER2 blockade; scFv antibody; Targeted therapy; Triple inhibition

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; HUMAN; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES;

EID: 84907988764     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-1854-8     Document Type: Article

References (51)

1. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. Gene. 1995;159(1):19–27.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
4. Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol. 2005;20(3):1005–15.
5. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011;11(9):793–800.
6. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011;71(5):1871–82.
7. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28(6):803–14.
8. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010;16(5):1509–15.
9. Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo. Clin Cancer Res. 2005;11(5):2008–17.
10. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
11. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429–40.
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639–48.
13. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8:215.
14. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.
15. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65(2):473–82.
16. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. 2012;2:62.
17. Sheridan C. FDA approves pertuzumab. Nat Biotechnol. 2012;30(7):570.
18. Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82.
19. Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, et al. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat. 2012;133(2):511–21.
20. Drucker AM, Wu S, Dang CT, Lacouture ME. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012;135(2):347–54.
21. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.
22. Liu F, Lu Q, Ye X, Fang C, Zhao Y, Liang M, et al. Cancer gene therapy of adenovirus-mediated anti-4–1BB scFv in immunocompetent mice. Cancer Biol Ther. 2008;7(3):448–53.
23. Monnier PP, Vigouroux RJ, Tassew NG. In vivo applications of single chain Fv (variable domain) (scFv) fragments. Antibodies. 2013;2:193–208.
24. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 1993;6(8):989–95.
25. Accardi L, Di Bonito P. Antibodies in single-chain format against tumour-associated antigens: present and future applications. Curr Med Chem. 2010;17(17):1730–55.
26. Dantas-Barbosa C, de Macedo BM, Maranhao AQ. Antibody phage display libraries: contributions to oncology. Int J Mol Sci. 2012;13(5):5420–40.
27. Zhao A, Nunez-Cruz S, Li C, Coukos G, Siegel DL, Scholler N. Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. J Immunol Methods. 2011;363(2):221–3.
28. Nejatollahi F, Asgharpour M, Jaberipour M. Down-regulation of vascular endothelial growth factor expression by anti-Her2/neu single chain antibodies. Med Oncol. 2012;29:378–83.
29. Cohen S. Cancer: past, present, and future. eBookIt.com (2013). http://www.barnesandnoble.com/w/cancer-sheldon-cohen-md-facp/1116226154?ean=2940148464273.
30. Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129(2):263–73.
31. Awada A, Bozovic-Spasojevic I, Chow L. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treat Rev. 2012;38(5):494–504.
32. Wong ALA, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer. 2012;2012:415170.
33. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71.
34. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6.
35. Widakowich C, de Castro JG, de Azambuja E, Dinh P, Awada A. Side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007;12(12):1443–55.
36. Ren XR, Wei J, Lei G, Wang J, Lu J, Xia W, et al. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. Breast Cancer Res. 2012;14(3):R89.
37. Liu D, Wang C, Li C, Zhang X, Zahng B, Mi Z, et al. Production and Characterization of a humanized single-chain antibody against human integrin αvβ3 protein. J Biol Chem. 2011;286:24500–7.
38. Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005;65(2):650–6.
39. Wang JN, Feng JN, Yu M, Xu M, Shi M, Zhou T, et al. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies. Mol Immunol. 2004;40(13):963–9.
40. Kennel SJ. Effects of target antigen competition on distribution of monoclonal antibody to solid tumors. Cancer Res. 1992;52:1284–90.
41. Banappagari S, Ronald S, Satyanarayanajois SD. Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. Medchemcomm. 2011;2(8):752–9.
42. Nahta R. Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol. 2012;2012:428062.
43. Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. BMC Cancer. 2012;12:45.
44. Abraham J. Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer. Commun Oncol. 2012;9:42–4.
45. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264–75.
46. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, et al. HER2 dimerization inhibitor pertuzumab-mode of action and clinical data in breast cancer. Breast Cancer. 2013;8(1):49–55.
47. Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res. 2013;19(3):610–9.
48. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330–6.
49. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138–44.
50. Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer. 2010;126(12):2893–903.
51. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. Tumor penetration of single-chain Fv antibody molecules. Cancer Res. 2001;61(12):4750–5.